I thought I’d share my roundup of recent reviews that highlight the opportunities, challenges and current state-of-the-art in MRD analysis for solid tumours…enjoy!
- Moding 2021 (Cancer Discov.): Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease a review from Ash Alizadeh and Max Diehn’s groups at Stanford that describes the evidence supporting the value of ctDNA MRD in solid cancers and highlights key considerations in its application.
- Wan 2021 (Cell Med): Liquid biopsies for residual disease and recurrence. Jonathan Wan was the lead author on the 2017 Nat. Rev. Cancer liquid biopsy review, in this new review Wan et al present the current evidence for ctDNA-based testing for “residual disease and recurrence” and the emerging role of liquid biopsy in the monitoring and management of solid tumors.
- Peng 2021 (Front. Oncol.): Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives
- Ulrich 2021 (Cancers): Detection of Tumor Recurrence via Circulating Tumor DNA Profiling in Patients with Localized Lung Cancer: Clinical Considerations and Challenges
- Honore 2021 (Cancers): Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact
- Larribère & Martens 2021 (Cancers): Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
- Nagasaka 2021 (Mol. Cancer): Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer highlights the recent research on liquid biopsy in #NSCLC, not limited to ctDNA, and focus on novel methods such as micro RNAs and long non-coding RNAs.
I’d also give a little shout out to
- Luo 2021 (Trends Mol. Med.): Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA if you’ve been following the GRAIL technology then you may be interested in this review, which focuses on methylation methods for ctDNA.